Moderna to pay up to $2.25B to end mRNA vaccine patent fight

Core Insights - Moderna has reached a settlement of up to $2.25 billion with Arbutus Biopharma and Genevant Sciences, resolving a legal dispute over technology used in its mRNA vaccines [9] - The settlement includes an upfront payment of $950 million and avoids future royalties on mRNA vaccine sales, which is seen as a relief for the company amid financial stress from declining COVID vaccine sales [7][9] - The agreement was viewed positively by investors, leading to a 9% increase in Moderna's share price, reflecting relief over avoiding a potentially more damaging financial outcome [8][9] Legal Dispute - The legal conflict involved claims over the ownership of lipid nanoparticles (LNPs) used in Moderna's mRNA vaccine delivery, which were developed by other companies, including Arbutus [4][3] - Genevant's CEO expressed satisfaction with the settlement, highlighting the recognition of their contribution to pandemic response [6] Financial Implications - The settlement allows Moderna to avoid a larger payout that could have significantly impacted its financial stability, as the original claims sought around $5 billion [9] - Analysts noted that the outcome prevents further strain on Moderna's balance sheet and future profit margins [8]